isabelobrien, Author at European Medical Journal - Page 23 of 65

5 minutes with... Jaime Manzanera, Eisai

Jaime Manzanera, EMEA Brand Director, Oncology, Eisai, shares his perspective on maximising ROI in pharmaceutical marketing and more.

Frederik-Schjesvold

Hema Now: Episode 10: Shaping the Future of Myeloma

Fredrik Schjesvold, Head of the Oslo Myeloma Center, Oslo University Hospital, and Head of the Norwegian myeloma association joins the show.

Handshake on a green background

Novartis to acquire Anthos Therapeutics for $925m

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone Life Sciences.

Martin Price, J&J

J&J’s Martin Price on World Cancer Day 2025 – Part 2

Uncover more of Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson’s thoughts on the oncology space

Two hands moving towards each other as if they are going to shake hands

Lupus nephritis drug delivers promising results, says Roche

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked effective options.

Lungs

Qureight and Avalyn unite to advance pulmonary fibrosis treatment

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive pulmonary fibrosis.

Engaging the medical mind: Does interactivity improve recall?

Recall matters when it comes to medical content. Find out how knowledge can be better retained through interactive medical education.

First and only chikungunya vaccine approved in UK

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the MHRA.

Dave Cescon

Onc Now: Episode 10: Transforming Breast Cancer Care

Join Dr Dave Cescon as he shares insights into the evolving landscape of breast cancer care and translational research.

J&J’s Martin Price on World Cancer Day 2025 – Part 1

A World Cancer Day edition of the podcast, with Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, J&J.